Patents Assigned to ASCEND BIOPHARMACEUTICALS LTD
-
Publication number: 20230183297Abstract: The present invention relates to methods of treating a disease characterised by aberrant cell proliferation (e.g., a cancer) in a human subject in need thereof. In particular, the present invention relates to treating the above conditions by administering a therapeutically effective amount of at least one agent that increases activation of a receptor of at least one type II interferon and/or type I interferon, and administering to the subject at least one agent that inhibits the Hedgehog (Hh) signalling pathway (e.g., Vismodegib). Also provided are pharmaceutical compositions, including controlled release pharmaceutical compositions, containing at least one agent that increases activation of a receptor of at least one type II interferon and/or type I interferon (e.g., a checkpoint inhibitor), an inhibitor of Hh signalling pathway, and a controlled release matrix such as a SiO2 matrix gel.Type: ApplicationFiled: October 21, 2022Publication date: June 15, 2023Applicant: ASCEND BIOPHARMACEUTICALS LTDInventors: Clement Leong, Geoffrey Pietersz
-
Publication number: 20230065168Abstract: Provided are methods of treating skin cancer in an individual in need thereof by administering to the individual vismodegib and a replication-deficient type 5 adenovirus for expression of interferon gamma.Type: ApplicationFiled: March 30, 2022Publication date: March 2, 2023Applicants: ASCEND BIOPHARMACEUTICALS LTD, Genentech, Inc.Inventors: Clement Leong, Geoffrey Pietersz, Edward F. McKenna, JR.
-
Publication number: 20220235097Abstract: The present invention relates to methods of treating a disease characterised by aberrant cell proliferation (e.g., a cancer) in a human subject in need thereof. In particular, the present invention relates to treating the above conditions by administering a therapeutically effective amount of at least one agent that increases activation of a receptor of at least one type II interferon and/or type I interferon, and administering to the subject at least one agent that inhibits the Hedgehog (Hh) signalling pathway (e.g., Vismodegib). Also provided are pharmaceutical compositions, including controlled release pharmaceutical compositions, containing at least one agent that increases activation of a receptor of at least one type II interferon and/or type I interferon (e.g., a checkpoint inhibitor), an inhibitor of Hh signalling pathway, and a controlled release matrix such as a SiO2 matrix gel.Type: ApplicationFiled: February 26, 2021Publication date: July 28, 2022Applicant: ASCEND BIOPHARMACEUTICALS LTDInventors: Clement Leong, Geoffrey Pietersz
-
Patent number: 11273170Abstract: The present invention relates to methods of treating cancer in a human subject in need thereof. In particular, the present invention relates to treating a cancer by administering a recombinant virus which expresses one or more biotherapeutic agents in a subject, and administering to the subject a nucleotide analogue or nucleotide precursor analogue chemotherapeutic agent. The invention further relates to method for treating cancer by administering a nucleotide analogue or nucleotide precursor analogue chemotherapeutic agent and a caspase inhibitor, and, optionally, also administering a recombinant virus expressing one or more biotherapeutic agents in the subject. The invention also relates to a method for treating cancer by administering purified interferon gamma to a subject and administering to the subject a nucleotide analogue or nucleotide precursor analogue chemotherapeutic agent.Type: GrantFiled: July 24, 2017Date of Patent: March 15, 2022Assignee: Ascend Biopharmaceuticals LtdInventor: Clement Leong
-
Publication number: 20210038660Abstract: The present invention relates generally to recombinant adenoviral pharmaceutical formulations. More particularly, the present invention relates to SiO2-gel-based controlled release recombinant adenoviral pharmaceutical formulations.Type: ApplicationFiled: July 22, 2020Publication date: February 11, 2021Applicant: Ascend Biopharmaceuticals LtdInventors: Clement Leong, Geoffrey Allan Pietersz
-
Publication number: 20190269711Abstract: The present invention relates to methods of treating cancer in a human subject in need thereof. In particular, the present invention relates to treating a cancer by administering a recombinant virus which expresses one or more biotherapeutic agents in a subject, and administering to the subject a nucleotide analogue or nucleotide precursor analogue chemotherapeutic agent. The invention further relates to method for treating cancer by administering a nucleotide analogue or nucleotide precursor analogue chemotherapeutic agent and a caspase inhibitor, and, optionally, also administering a recombinant virus expressing one or more biotherapeutic agents in the subject. The invention also relates to a method for treating cancer by administering purified interferon gamma to a subject and administering to the subject a nucleotide analogue or nucleotide precursor analogue chemotherapeutic agent.Type: ApplicationFiled: July 24, 2017Publication date: September 5, 2019Applicant: Ascend Biopharmaceuticals LtdInventor: Clement Leong
-
Patent number: 10344261Abstract: The present invention provides an immunomodulatory compound comprising a carbohydrate polymer comprising mannose, wherein the carbohydrate polymer is conjugated to at least one immune modulator. The present invention also provides for the use of this compound in immunomodulatory compositions for vaccination and gene therapy methods, together with processes for its preparation.Type: GrantFiled: November 9, 2012Date of Patent: July 9, 2019Assignee: ASCEND BIOPHARMACEUTICALS LTDInventors: Geoffrey Alan Pietersz, Clement Leong